Dr. Valle Honored as Professor Emeritus
The Cholangiocarcinoma Foundation is proud to announce that Dr. Juan Valle, Chief Medical Officer of the Cholangiocarcinoma Foundation (CCF), has been honored with the title of Professor Emeritus at the University of Manchester. This prestigious recognition is a testament to Dr. Valle’s extraordinary contributions to oncology and his relentless commitment to advancing rare cancer research, particularly cholangiocarcinoma (bile duct cancer).
Dr. Valle’s appointment as Professor Emeritus is a significant milestone in his distinguished career. This title is reserved for faculty members who have demonstrated exceptional service, academic achievement, and influence in their field. It recognizes Dr. Valle’s profound impact on medical oncology, reinforcing his esteemed position within the global medical community.
Before joining CCF, Dr. Valle served as Professor of Medical Oncology at the University of Manchester and as an Honorary Consultant at The Christie NHS Foundation Trust. His pioneering work has been instrumental in establishing the first standard of care for advanced cholangiocarcinoma patients. As a founding member of the International Biliary Tract Cancer Consortium, Dr. Valle has played a key role in shaping research and treatment approaches for cholangiocarcinoma on a global scale.
At CCF, Dr. Valle leads our research initiatives, guiding the development of innovative treatment approaches for cholangiocarcinoma. His expertise and leadership are invaluable assets to our mission of finding a cure and improving the quality of life for patients with this rare and aggressive cancer.
Throughout his career, Dr. Valle has authored over 300 scientific articles and received numerous research grants, furthering our understanding of pancreatic, biliary, and neuroendocrine cancers. His research has set new standards for patient care, making a lasting impact on the field.
Dr. Valle’s contributions have already made a significant difference in the lives of cholangiocarcinoma patients, and his work with CCF will continue to drive advancements in research, education, and advocacy.